Is there a “non-MAO” macromolecular target for L-rmdeprenyl?: Studies on MAOB mutant mice
- 14 August 1998
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 63 (12) , PL181-PL186
- https://doi.org/10.1016/s0024-3205(98)00370-1
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Increased stress response and β–phenylethylamine in MAOB–deficient miceNature Genetics, 1997
- Chronic Treatment of Syrian Hamsters With Low-Dose Selegiline Increases Life Span in Females But Not MalesNeurobiology of Aging, 1997
- l‐(−)‐Desmethylselegiline, a Metabolite of Selegiline [l‐(−)‐Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In VitroJournal of Neurochemistry, 1997
- Selegiline stimulates biosynthesis of cytokines interleukin-1β and interleukin-6NeuroReport, 1996
- L-Deprenyl Treatment in Aged Mice Slightly Increases Life Spans, and Greatly Reduces Fecundity by Aged MalesThe Journals of Gerontology: Series A, 1996
- Suppression of Hydroxyl Radical Formation and Protection of Nigral Neurons by l‐Deprenyl (Selegiline)Annals of the New York Academy of Sciences, 1996
- Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats. Further evidenceLife Sciences, 1993
- Pharmacological basis of the therapeutic effect of (−)deprenyl in age‐related neurological diseasesMedicinal Research Reviews, 1992
- The molecular pharmacology of L-deprenylEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985